Replies to post #141539 on PharmaCyte Biotech Inc (PMCB)

[Edward]

-PMCB is doubling the number of Directors.

No.

PMCB has always had 7 directors, they are just up for reelection. No increase in directors the nominees are the same people on the board now, there still will be 7.

From the 8-K:

PROPOSAL NO. 1 ELECTION OF DIRECTORS

Our Board currently has seven members. Based on the recommendation of the Board’s Nominating Committee, the Board has nominated each of the following seven directors to serve until the 2022 Annual Meeting of Stockholders or until their successors are duly elected and qualified: Kenneth L. Waggoner,Gerald W. Crabtree, PhD, Thomas Liquard, Thomas C. K. Yuen, Michael M. Abecassis, MD, Raymond C.F. Tong, MD and Carlos A. Trujillo. Each of thenominees currently serves as a director.Each of the nominees has agreed to serve as a director if elected.


Current board:

https://pharmacyte.com/company/board-directors/

[oldmusky]

PMCB does not qualify for the Nasdaq. Not even close. You need revenue and you need to be in dollar land. Pmcb will never be on a major exchange. Bankruptcy coming once investors stop falling for this dream/nightmare.

[DragonBear]

PMCB un-likely up-listing (NASDAQ)

They do not qualify. See this

Post

1. More Directors. More Directors to pay.

2. Increase A/S to $50B to increase share dilution. Along with the potential of cranking up toxic debt notes.

3. To approve PharmaCyte’s 2021 Equity Incentive Plan to further enhance the wealth of insiders.

4.

to ratify PharmaCyte’s appointment of Armanino LLP...They probably need this accountant so they have one year of certified year end statements.

Every time they submit a 10K it needs an Armanino to sign off that it has been audited. Nothing new. Neither is Armanino new -been around since 2017.

Net result: PMCB wants to pay out to more BOD members. Raise the A/S up into the clouds at 50B, so they can massively dilute the shares, increase compensation, and keep Armanino around for another yr. Yippee!